Penzberg, Germany, February 9, 2012
Roche’s xCELLigence Cardio Instrument Used to Detect Beating Rhythm and Proarrhythmic Effects of Compounds in Stem Cell-Derived Cardiomyocytes
In an effort to improve preclinical cardiotoxicity assays, reduce drug testing attrition rates, and ensure drug safety, collaborating scientists at the University Medical Center Utrecht in the Netherlands, and Bioscience Department of AstraZeneca R&D, Mölndal, Sweden, have tested Roche’s xCELLigence Cardio Instrument. Their goal was to determine whether impedance recordings are a useful way to detect compound effects on beating frequency of cardiomyocytes, derived either from human induced pluripotent stem cells (hiPS), or from mouse embryonic stem cells (mESC). The xCELLigence Cardio Instrument is an impedance sensing instrument capable of reading signals at high sampling rates, making it possible to measure the contraction movements of cardiomyocytes in contact with sensor microelectrodes.
In this study (1), the effects of nine compounds were tested on beating frequency (beats per minute, bpm) of hiPS and mESC cardiomyocytes. The authors reported, “The results of this initial study show that, under the right conditions, the beating frequency of a monolayer of cells can be stably recorded over several days. In addition, the xCELLigence System detects changes in beating frequency and amplitude caused by added reference compounds.”
The authors conclude that xCELLigence Cardio instrument has potential for 96-well-throughput cardiotoxicity screening of the effects of compounds on rhythmic beating patterns of cardiomyocytes. They underscored the need for continuous improvements in the maturation of available cardiomyocytes and in further validation of the assay on an extended set of reference compounds with known in-vivo effects. They also indicated that the production of distinct subtypes of ventricular, atrial and nodal cardiomyocytes could open up new areas of screening for arrhythmia and cardiotoxicity.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.
For life science research only. Not for use in diagnostic procedures.
XCELLIGENCE is a trademark of Roche.
E-PLATE is a registered trademark of ACEA Biosciences, Inc. in the US.
Other brands or product names are trademarks of their respective holders.
(1) Malin K.B. Jonsson, Qing-Dong Wang, Bruno Becker: Impedance-Based Detection of Beating Rhythm and Proarrhythmic Effects of Compounds on Stem Cell-Derived Cardiomyocytes. ASSAY and Drug Development Technologies. December 2011: 589-599.